Response to Letters Regarding Article, “Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects”

• DOI: 10.1161/circulationaha.112.096982
• Publication Date: 2012-04-23T21:30:03Z
• Authors: Elise S. Eerenberg; Meertien K. Sijpkens; Joost C.M. Meijers; Harry R. Buller; Marcel Levi; Pieter W. Kamphuisen
• Keywords: anticoagulant therapy; prothrombin complex; letter; 01 natural sciences; 0104 chemical sciences; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; blood clotting factor 7; priority journal; melagatran; dabigatran; human; randomized controlled trial (topic); anticoagulation; rivaroxaban; outcome assessment

We appreciate the remarks made by Bernstein et al and by Marlu et al. In our study, a single dose of the prothrombin complex concentrate (PCC) Cofact normalized the anticoagulant effect of rivaroxaban, but not that of dabigatran, measured by means of coagulation assays in healthy subjects.1 We agree with the comment by Marlu et al that these tests may insufficiently represent a definitive beneficial effect in patients with hemorrhage. To establish PCCs as effective reversing agents …